Well Referenced

Tag: testosterone cypionate

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

This 2018 open-label, phase 2, multicohort study evaluated the efficacy of bipolar androgen therapy (BAT) in 30 men with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after enzalutamide treatment. BAT involved intramuscular testosterone cypionate (400 mg every 28 days) combined with luteinizing hormone-releasing hormone agonist therapy. The primary endpoint,

Read More »
June 26, 2025 No Comments

Bipolar Androgen Therapy Sensitizes Castration-Resistant Prostate Cancer to Subsequent Androgen Receptor Ablative Therapy

This 2021 study evaluated the efficacy of bipolar androgen therapy (BAT) as a first-line treatment for castration-resistant prostate cancer (CRPC). In Cohort C of the RESTORE trial, 29 patients received 400 mg of testosterone cypionate every 28 days alongside luteinizing hormone-releasing hormone agonists or antagonists. The primary endpoint, PSA50 response

Read More »
June 26, 2025 No Comments